Nevro Corp. (NVRO)
NYSE: NVRO · Real-Time Price · USD
5.78
-0.01 (-0.17%)
At close: Mar 11, 2025, 4:00 PM
5.79
+0.01 (0.17%)
After-hours: Mar 11, 2025, 8:00 PM EST
Nevro Revenue
In the year 2024, Nevro had annual revenue of $408.52M, down -3.92%. Nevro had revenue of $105.55M in the quarter ending December 31, 2024, a decrease of -9.15%.
Revenue (ttm)
$408.52M
Revenue Growth
-3.92%
P/S Ratio
0.52
Revenue / Employee
$336,229
Employees
1,215
Market Cap
218.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 408.52M | -16.66M | -3.92% |
Dec 31, 2023 | 425.17M | 18.81M | 4.63% |
Dec 31, 2022 | 406.37M | 19.46M | 5.03% |
Dec 31, 2021 | 386.91M | 24.86M | 6.87% |
Dec 31, 2020 | 362.05M | -28.21M | -7.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NVRO News
- 7 days ago - Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results - PRNewsWire
- 4 weeks ago - NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO - Business Wire
- 7 weeks ago - Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - PRNewsWire
- 2 months ago - Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results - PRNewsWire
- 3 months ago - Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Benzinga
- 4 months ago - New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches - PRNewsWire
- 4 months ago - Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally - PRNewsWire
- 4 months ago - Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript - Seeking Alpha